Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Rectal Neoplasms 2Neoplasms 1NSCLC 1Liver Neoplasms 1Hepatoblastoma 1

Interventions

Pemetrexed 2Gefitinib 2spartalizumab 1aflutinib 1Tyrosine Kinase Inhibitors 1Thalidomide 1Radiosurgery 1Platinum 1Immune Checkpoint Inhibitors 1Drug Therapy 1Axitinib 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NSCLC × Immune Checkpoint Inhibitors × Clear all
NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

The First Affiliated Hospital of Zhengzhou University

Phase 2/3 Unknown
150 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡